These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22169459)

  • 1. Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.
    Miyata H; Yano M; Yasuda T; Hamano R; Yamasaki M; Hou E; Motoori M; Shiraishi O; Tanaka K; Mori M; Doki Y
    Clin Nutr; 2012 Jun; 31(3):330-6. PubMed ID: 22169459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.
    Miyata H; Yano M; Yasuda T; Yamasaki M; Murakami K; Makino T; Nishiki K; Sugimura K; Motoori M; Shiraishi O; Mori M; Doki Y
    Nutrition; 2017 Jan; 33():204-210. PubMed ID: 27644137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between immunological parameters and the severity of neutropenia and effect of enteral nutrition on immune status during neoadjuvant chemotherapy on patients with advanced esophageal cancer.
    Motoori M; Yano M; Yasuda T; Miyata H; Peng YF; Yamasaki M; Shiraishi O; Tanaka K; Ishikawa O; Shiozaki H; Doki Y
    Oncology; 2012; 83(2):91-100. PubMed ID: 22777298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
    Miyata H; Sugimura K; Motoori M; Fujiwara Y; Omori T; Yanagimoto Y; Ohue M; Yasui M; Miyoshi N; Tomokuni A; Akita H; Kobayashi S; Takahashi H; Yano M
    Anticancer Res; 2017 Jun; 37(6):3053-3059. PubMed ID: 28551644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
    Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
    Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
    Miyoshi N; Yano M; Takachi K; Kishi K; Noura S; Eguchi H; Yamada T; Miyashiro I; Ohue M; Ohigashi H; Sasaki Y; Ishikawa O; Doki Y; Imaoka S
    J Surg Oncol; 2009 Apr; 99(5):302-6. PubMed ID: 19170110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer.
    Shimakawa T; Naritaka Y; Asaka S; Isohata N; Murayama M; Konno S; Yoshimatsu K; Shiozawa S; Katsube T; Ogawa K
    Anticancer Res; 2008; 28(4C):2321-6. PubMed ID: 18751413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of combined chemotherapy with nedaplatin, adriamycin, and 5-FU (NAF), and clinical factors affecting its effect in patients with advanced esophageal cancer].
    Hasegawa H; Fujitani K; Hirao M; Nakazuru S; Mita E; Tsujinaka T
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2591-5. PubMed ID: 22189224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Hainsworth JD; Gray JR; Thomas M; Whitworth PL; Davis JL; Greco FA
    Cancer J Sci Am; 1999; 5(2):84-91. PubMed ID: 10198730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
    Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
    Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
    Mohammadianpanah M; Ashouri Y; Hoseini S; Amadloo N; Talei A; Tahmasebi S; Nasrolahi H; Mosalaei A; Omidvari S; Ansari M; Mosleh-Shirazi MA
    Breast Cancer Res Treat; 2012 Apr; 132(3):853-61. PubMed ID: 22002564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
    Lee J; Lee KE; Im YH; Kang WK; Park K; Kim K; Shim YM
    Ann Thorac Surg; 2005 Oct; 80(4):1170-5. PubMed ID: 16181835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
    Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.
    Voelter V; Schuhmacher C; Busch R; Peschel C; Siewert JR; Lordick F
    Ann Thorac Surg; 2004 Sep; 78(3):1037-41. PubMed ID: 15337044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of irradiated lung volumes on perioperative morbidity and mortality in patients after neoadjuvant radiochemotherapy for esophageal cancer.
    Dähn D; Martell J; Vorwerk H; Hess CF; Becker H; Jung K; Hilgers R; Wolff HA; Hermann RM; Christiansen H
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):44-52. PubMed ID: 19679407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer.
    Uno T; Isobe K; Kawakami H; Ueno N; Kobayashi H; Shimada H; Mastubara H; Okazumi S; Nabeya Y; Shiratori T; Ochiai T; Kawata T; Ito H
    Anticancer Res; 2004; 24(4):2483-6. PubMed ID: 15330202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel-Cisplatin-5-Fluorouracil Represents Sensitivity: A Phase II Study.
    Matsumoto A; Nishikawa K; Yuda M; Tanaka Y; Tanishima Y; Arakawa Y; Ishibashi Y; Sakuyama T; Omura N; Mitsumori N; Aiba K; Yanaga K
    Anticancer Res; 2016 Apr; 36(4):1937-42. PubMed ID: 27069183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.